P/Q-type Ca++ CP α1A CRISPR/Cas9 KO Plasmid (m): sc-419400
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- P/Q-type Ca++ CP α1A CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the P/Q-type Ca++ CP α1A genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: P/Q-type Ca++ CP α1A Antibody (C-2): sc-390004
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
P/Q-type Ca++ CP α1A CRISPR/Cas9 KO Plasmid (m) | sc-419400 | 20 µg | $397.00 |
Overview
Cacna1a encodes the pore-forming α1A subunit of the P/Q-type voltage-gated calcium channel (CaV2.1), a major route for activity-dependent Ca2+ entry in neurons. CaV2.1 couples membrane depolarization to synaptic vesicle exocytosis, shaping neurotransmitter release probability, short-term plasticity, and circuit excitability through Ca2+-dependent signaling pathways. Channel function is integrated with presynaptic active zone proteins and downstream Ca2+ sensors that regulate vesicle docking and fusion. Genetic and functional disruption of CACNA1A/CaV2.1 has been linked to neurological phenotypes involving altered synaptic transmission and network instability, making it a key target for mechanistic studies of neurophysiology.
P/Q-type Ca++ CP α1A CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Cacna1a gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Cacna1a together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Cacna1a open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish P/Q-type Ca++ CP α1A protein expression.
This CRISPR knockout system enables efficient generation of Cacna1a-deficient cell models for investigation of P/Q-type Ca++ CP α1A signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Cacna1a exon(s) critical for P/Q-type Ca++ CP α1A function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Cacna1a genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by P/Q-type Ca++ CP α1A CRISPR/Cas9 KO Plasmid (m) and P/Q-type Ca++ CP α1A CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Cacna1a locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by P/Q-type Ca++ CP α1A HDR Plasmid (m) and P/Q-type Ca++ CP α1A HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Cacna1a homology arms to support homology-directed repair at defined Cacna1a target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.